论文部分内容阅读
目的观察氨磷汀配合FOLFIRI方案(伊立替康+5-氟尿嘧啶+亚叶酸钙)治疗晚期结直肠癌的疗效及对正常组织的保护作用和安全性。方法56例晚期结直肠癌,随机分为两组,对照组28例,接受FOLFIRI方案。治疗组28例,化疗方案同对照组,化疗前30 min应用氨磷汀500 mg静滴,15min滴完。化疗4周期后复查,评价疗效和毒性。结果两组总有效率无统计学意义(P>0.05)。治疗组毒副反应明显低于对照组,两者差异有统计学意义(P<0.05)。结论氨磷汀能有效减低FOLFIRI方案的毒副反应,且不降低其抗癌作用。
Objective To observe the effect of amifostine combined with FOLFIRI regimen (irinotecan + 5-fluorouracil + leucovorin) in the treatment of advanced colorectal cancer and its protective effect and safety on normal tissues. Methods 56 cases of advanced colorectal cancer were randomly divided into two groups, the control group of 28 patients received FOLFIRI program. The treatment group 28 cases, the same chemotherapy and control group, 30 min before chemotherapy with amifostine 500 mg intravenous drip, 15min drip finished. 4 cycles after chemotherapy review, evaluation of efficacy and toxicity. Results The total effective rate was no significant difference between the two groups (P> 0.05). The side effects in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion Amifostine can effectively reduce the toxic side effects of FOLFIRI regimen and does not reduce its anticancer effect.